NWMP
PTGX icon

Noble Wealth Management PBC’s Protagonist Therapeutics PTGX Stock Holding History

Noble Wealth Management PBC’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$981 Buy
+8
New +$836 ﹤0.01% 709

Other funds holding PTGX

NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Noble Wealth Management PBC's PTGX Position: Q2 2026 in Review

Noble Wealth Management PBC opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 8 shares worth $981. The stake represents ﹤0.01% of the portfolio and ranks #709 among its holdings.

59 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Noble Wealth Management PBC held 8 shares of Protagonist Therapeutics worth $981 as of Q2 2026.
  • Protagonist Therapeutics was a new Noble Wealth Management PBC position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Noble Wealth Management PBC's portfolio in Q2 2026, its #709 holding.
  • 59 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Noble Wealth Management PBC's 13F filing for Q2 2026, filed 1 Jul 2026.